Literature DB >> 22542611

Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles.

Wei Li1, He Zhao, Weizhu Qian, Huafei Li, Li Zhang, Zengwei Ye, Ge Zhang, Mao Xia, Jinfeng Li, Jie Gao, Bohua Li, Geng Kou, Jianxin Dai, Hao Wang, Yajun Guo.   

Abstract

Micelles with high in vivo serum stability and intratumor accumulation post intravenous (i.v.) injection are highly desired for promoting chemotherapy. Herein, we finely synthesized and tailored well-defined anti-Her2 antibody Fab fragment conjugated immunomicelles (FCIMs), which showed interesting dual targeting function. The thermosensitive poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)(118) (PID(118)) shell with volume phase transition temperature (VPTT: 39 °C) and the anchored anti-Her2 Fab moiety contributed to the passive and active targeting, respectively. The doxorubicin (DOX) loading capacity of such FCIMs was successfully increased about 2 times by physically enhanced hydrophobicity of inner reservoir without structural deformation. The cellular uptake and intracellular accumulation of DOX by temperature regulated passive and antibody navigated active targeting was 4 times of Doxil. The cytotoxicity assay against Her2 overexpression gastric cancer cells (N87s) showed that the IC50 of the FCIMs was ≈ 9 times lower than that of Doxil under cooperatively targeting by Fab at T > VPTT. FCIMs showed high serum stability by increasing the corona PID(118) chain density (S(corona)/N(agg)). In vivo tissue distribution was evaluated in Balb/c nude mice bearing gastric cancer. As observed by the IVIS(®) imaging system, the intratumor accumulation of such finely tailored FCIMs system was obviously promoted 24 h post i.v. administration. Due to the high stability and super-targeting, the in vivo xenografted gastric tumor growth was significantly inhibited with relative tumor volume <2 which was much smaller than ≈ 5 of the control. Consequently, such finely tailored FCIMs with anti-Her2 active and temperature regulated passive dual tumor-targeting function show high potent in chemotherapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542611     DOI: 10.1016/j.biomaterials.2012.04.016

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  23 in total

Review 1.  Treatment of early gastric cancer in the Western World.

Authors:  Elfriede Bollschweiler; Felix Berlth; Christoph Baltin; Stefan Mönig; Arnulf H Hölscher
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

2.  Roles of p38 and JNK protein kinase pathways activated by compound cantharidin capsules containing serum on proliferation inhibition and apoptosis of human gastric cancer cell line.

Authors:  Yonghao Sun; Dejuan Zhang; Mao Mao; Yangping Lu; Ning Jiao
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

Review 3.  Molecular targeted treatment and drug delivery system for gastric cancer.

Authors:  Lanxin Jiang; Xiaomin Gong; Wangdi Liao; Nonghua Lv; Runwei Yan
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-07       Impact factor: 4.553

Review 4.  Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.

Authors:  Virginia Del Solar; María Contel
Journal:  J Inorg Biochem       Date:  2019-07-18       Impact factor: 4.155

5.  High Expression of UPK3A Promotes the Progression of Gastric Cancer Cells by Inactivating p53 Pathway.

Authors:  Deliang Xu; Jing Guo; Hongwei Xu
Journal:  Anal Cell Pathol (Amst)       Date:  2022-06-21       Impact factor: 4.133

Review 6.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions.

Authors:  Alexander Koshkaryev; Rupa Sawant; Madhura Deshpande; Vladimir Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2012-09-03       Impact factor: 15.470

7.  Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors.

Authors:  Wei Li; Huafei Li; Jinfeng Li; Huajing Wang; He Zhao; Li Zhang; Yu Xia; Zengwei Ye; Jie Gao; Jianxin Dai; Hao Wang; Yajun Guo
Journal:  Int J Nanomedicine       Date:  2012-08-22

8.  Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models.

Authors:  Yoshiyuki Yamamoto; Ichinosuke Hyodo; Yoshikatsu Koga; Ryo Tsumura; Ryuta Sato; Toshihumi Obonai; Hirobumi Fuchigami; Fumiaki Furuya; Masahiro Yasunaga; Mitsunori Harada; Yasuki Kato; Atsushi Ohtsu; Yasuhiro Matsumura
Journal:  Cancer Sci       Date:  2015-03-23       Impact factor: 6.716

9.  Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.

Authors:  Hua-Fei Li; Cong Wu; Ting Chen; Ge Zhang; He Zhao; Chang-Hong Ke; Zheng Xu
Journal:  Int J Nanomedicine       Date:  2015-07-30

10.  Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.

Authors:  Huafei Li; Ge Zhang; Cheng Jiang; Fulei Zhang; Changhong Ke; He Zhao; Yun Sun; Mengxin Zhao; Di Chen; Xiandi Zhu; Li Zhang; Bohua Li; Jianxin Dai; Wei Li
Journal:  Oncotarget       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.